Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2003 Jan 15;101(2):391-8. Epub 2002 Sep 19.

Radioimmunotherapy of non-Hodgkin lymphomas.

Author information

  • 1Georgetown University Hospital, Lombardi Cancer Center, Washington, DC 20007, USA.

Abstract

Enthusiasm for the use of monoclonal antibodies, such as rituximab, has markedly changed the approach to patients with non-Hodgkin lymphomas (NHLs). Nevertheless, more effective therapies are needed. Radioimmunotherapy as a form of targeted radiation therapy may add significantly to our therapeutic options. Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and Drug Administration, and iodine I 131 tositumomab have demonstrated a high level of activity in patients whose NHL has failed to respond to chemotherapy and rituximab. Toxicities have primarily included prolonged myelosuppression, with a potential risk of treatment-associated myelodysplastic syndrome and acute myelogenous leukemia. Ongoing clinical trials are attempting to better characterize the role of these promising agents.

PMID:
12393555
DOI:
10.1182/blood-2002-06-1793
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center